INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNITY FOR OVARIAN CANCER

共有29名患者进入了这项I期试验， 177 Lu-CC 49联合紫杉醇化疗（与 在放射免疫治疗之前给予干扰素以增强抗原 肿瘤的表达）。 符合本试验条件的患者为 接受过减瘤手术，随后接受辅助化疗，以及 在二次手术或成像扫描中有残留疾病，或 后来复发。 先前的一项研究已经确定了177 Lu的MTD- CC 49为45 mCi/m2。 当与干扰素一起给药时， 177 Lu-CC 49为40 mCi/m2。目前的研究使用了80%剂量的 MTD剂量的177 Lu-CC 49+干扰素沿着递增剂量的 腹腔注射紫杉醇。 一些国家的反应令人鼓舞 可评估的患者，研究正在进行中。

A total of 29 patients have ben entered on this phase I trial which gives a combination of 177Lu-CC49 in conjunction with Taxol chemotherapy (with interferon being given prior to radioimmunotherapy to enhance antigen expression of the tumor). Patients eligible for this trial are those who have received debulking surgery followed by adjuvant chemotherapy, and have residual disease on second look surgery or on imaging scans, or have subsequently relapsed. A previous study had determined the MTD of 177Lu- CC49 as being 45 mCi/m2. When administered with interferon the MTD of 177Lu-CC49 has been 40 mCi/m2. The current study uses an 80% dose of the MTD dose of 177Lu-CC49+interferon along with escalating doses of intraperitoneal Taxol. Encouraging responses have been seen in some of the patients who have been evaluable, and the study is ongoing.